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Abstract
Conventionally, phase I dose-nding trials aim to determine the maximum tolerated
1
dose (MTD) of a new drug under the assumption that both toxicity and ecacy mono-
tonically increase with the dose. This paradigm, however, is not suitable for some
molecularly targeted agents (MTAs), such as monoclonal antibodies, for which ecacy
often increases initially with the dose and then plateaus. For MTAs, the goal is to nd
the optimal dose, dened as the lowest safe dose that achieves the highest ecacy. We
develop a Bayesian phase I/II dose-nding design to nd the optimal dose. We em-
ploy a logistic model with a plateau parameter to capture the increasing-then-plateau
feature of the dose-ecacy relationship. We take the weighted likelihood approach to
accommodate for the case where ecacy is possibly late-onset. Based on observed data,
we continuously update the posterior estimates of toxicity and ecacy probabilities and
adaptively assign patients to the optimal dose. The simulation studies show that the
proposed design has good operating characteristics. This method is going to be applied
in more than two phase I clinical trials as no other method is available for this spe-
cic setting. We also provide an R package dfmta that can be download from CRAN
website.
Keywords: Dose-nding; Molecularly targeted agents; Oncology; Phase I; Phase II.
1 Introduction
Traditionally, phase I dose-nding trials aim to determine the maximum tolerated dose
(MTD) of a new drug that will be further investigated for ecacy in phase II. This
paradigm is built upon the assumption that both toxicity and ecacy monotonically
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increase with the dose, which is typically true for conventional cytotoxic agents. Re-
cently, molecularly targeted agents (MTAs) have emerged as a new therapeutic option
in oncology that has changed the practice of cancer patient care. For many MTAs,
e.g., monoclonal antibodies, the monotonicity assumption may be violated for ecacy
although it typically holds for toxicity. For example, the FDA guidance points out
\cancer vaccine trials have used the `3 + 3 design' and the results show that, except in
very rare situations, an MTD for a cancer vaccine may not be identied. In these trials,
the dose-toxicity curve may be so at that the highest dose that can be administered
is limited by manufacturing or anatomic issues rather than toxicity" [1]. As another
example, the ecacy of PTK/ZK (an orally active inhibitor of vascular endothelial
growth factor receptor tyrosine kinases) virtually does not change with the dose once it
reaches the threshold (or plateau) of 1000mg, which is below the MTD [2, 3]. Further
increasing the dose of PTK/ZK to the MTD does not improve its ecacy. As a result,
traditional dose-nding methods for cytotoxic agents are not always suitable for MTAs
because the MTAs do not necessarily need to be administered at their MTDs to achieve
maximal ecacy. Depending on the structure of the molecule and its type, some MTAs
can reach a plateau of ecacy. Therefore, for MTAs, we are interested in nding the bi-
ological optimal dose, which is dened as the lowest safe dose that achieves the highest
ecacy, i.e., the dose corresponding to the plateau changing point in the dose-ecacy
curve while satisfying certain toxicity requirements (see Figure 1).
A limited number of dose-nding methods have been proposed to handle the case
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Figure 1: Illustration of dose-toxicity and dose-ecacy relationships for MTAs.
where the dose-response curve rst increases with the dose and then reaches a plateau.
Hunsberger et al [4] proposed a phase II dose-escalation design, assuming a linear
regression model for the dose-response curve on the last three or four doses explored.
If the estimated slope is null or negative, the trial is terminated and the dose with the
highest response rate is selected as the optimal dose. Hirakawa [5] proposed another
dose-nding design by jointly modeling a binary toxicity outcome with a continuous
ecacy outcome, in which Mahalanobis distance was used to measure the desirability
of the dose for dose assignment. Cai et al [6] proposed a Bayesian phase I/II to handle
drug combination trials involving two MTAs when the dose-response curve plateaus
at high doses. Ivanova and Xiao [7] developed a phase II design to determine the
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minimum eective dose (MED), which does not necessarily correspond to the biological
optimal dose. More recently, Zang, Lee and Yuan [8] proposed nonparametric and
semiparametric approaches to nd the biological optimal dose for MTAs with unimodal
or plateaued dose-response curves.
This work is motivated by a phase I clinical trial initiated by the French Sarcoma
Group, for which some authors served as statistical collaborators. The goal of the
trial is to nd the biological optimal dose of propranolol for treating patients with
locally advanced or metastatic angiosarcoma. Stiles et al. [9] demonstrated that beta-
adrenergic inhibition blocks cell proliferation and induces apoptosis in a dose dependent
manner. Specically, using in vivo tumor models, they demonstrated that propranolol,
non-specic beta-adrenergic receptor inhibitor, shows remarkable ecacy in reducing
the growth of angiosarcoma tumors. Physicians are expecting an ecacy plateau for
this agent due to its action mechanism. Therefore, traditional MTD based dose nding
methods cannot be used for this trial.
The aim of this paper was to propose a practical phase I/II dose-nding design for
MTAs. We employ a logistic model with a plateau parameter to capture the increasing-
then-plateau feature of the dose-ecacy relationship. We take the weighted likelihood
approach to accommodate for the possibility that ecacy is late-onset in the sense that
ecacy takes a relatively long time to be assessed compared to toxicity (with respect
to the accrual rate), such that when the next new patient arrives, patients who have
enrolled into the trial have not completed their ecacy assessment yet [10, 11, 12]. We
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assume that toxicity monotonically increases with the dose and model it using a logistic
model. Based on observed data, we continuously update the posterior estimates of
toxicity and ecacy probabilities and adaptively assign patients to the optimal dose. We
conduct extensive simulation to examine the operating characteristics of the proposed
design.
This paper diers from our previous work on the combination of a cytotoxic agent
with a MTA [13] in several important aspects. In our previous work, we employed
the conventional greedy dose-assignment rule that always assigns new patients to the
currently estimated optimal dose. Such greedy myopic algorithm works reasonably
well when the number of investigational doses for the MTA is small. For example, in
the combination trial of a cytotoxic agent with a MTA, in order to control the total
number of investigational dose combinations within a practical range (e.g., < 12), the
number of investigational dose levels for the MTA is often small, e.g., combining 3
doses of the MTA with a cytotoxic agent with 3 doses results in a total of 9 dose
combinations. Therefore, the greedy dose-assignment rule often works well in that
setting. However, we have observed that the percentage of correct recommendation of
dose combinations at the end of the trial by our design were highly decreasing with the
number of dose levels for the MTA. Even in the single agent dose-nding trial we focus
here, when there are many (e.g.,  6) doses for the MTA, the greedy dose-assignment
rule becomes problematic and often causes the dose nding to get stuck in local maxima
(more details are provided in Section 2.4). In this paper, we propose several robust, well
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performing dose assignment rules to address this issue. The second dierence between
this paper and our previous work is that herein we propose a weighting based approach
to acknowledge and allow the use of partial information available to make the decision
of dose assignment for new patients. We also provide an R package dfmta, available
from CRAN website, to implement the proposed design.
2 Methods
2.1 Toxicity model
Consider a trial involving K doses of an MTA. We model the toxicity probability of the
kth dose level, denoted as  (k; 0; 1) =  k, using a logistic model as follows:
logit( k) = 0 + 1uk; (1)
where 0, 1 are unknown parameters, and uk is the \eective" dose associated with
dose level k, which typically diers from the actual clinical dosage. In (1), we require
1 > 0 so that toxicity monotonically increases with dose levels, as is often the case in
practice. Let ~ k denote the prior guess of toxicity probability (i.e. working model, or
skeleton) for dose level k, and ~0 and ~1 denote the prior estimates of 0 and 1 (for
instance means of the prior distributions). The \eective" dose uk is determined by
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back-solving the dose-toxicity model, i.e.,
uk =
(
log
 
~ k
1  ~ k
!
  ~0
)
=~1:
The reason that we use the \eective" dose, rather than the actual clinical dosage, in
the logistic regression is to regularize the estimate of  k to a practically reasonable
range (i.e., a priori, the estimate of  k matches our prior guess ~ k), thereby improving
the stability of the trial design. This is important because the small sample size of
phase I trials often results in very unreliable model tting, especially at the beginning
of the trial when there are only a few observations. Using the \eective" dose to t
regression models has been adopted previously in dose-nding studies [14, 15, 16].
Let yi denote the binary toxicity outcome (1 = toxicity, and 0 = no toxicity) for
patient i treated at the dose level xi 2 f1; : : : ; Kg, where i = 1; : : : ; N . After the
rst I patients are enrolled into the trial, the likelihood of the toxicity data Dtox =
f(x1; y1); : : : ; (xI ; yI)g is:
L(Dtoxj0; 1) =
IY
i=1
 yixi(1   xi)1 yi :
Letting f(0; 1) denote the prior distribution of 0 and 1, the posterior is then given
by:
f(0; 1jDtox) / L(Dtoxj0; 1)f(0; 1) (2)
8
We assume prior distributions are independent and take a vague normal prior N(0; 100)
for the intercept 0, and following Chevret [15], we assign the slope 1 an exponential
distribution with a rate parameter of 1, i.e. 1  Exp(1).
2.2 Ecacy model
An important feature of MTAs that distinguishes them from conventional cytotoxic
agents is that the dose-ecacy curves of MTAs do not necessarily increase with the
dose. For MTAs, ecacy is often expected to monotonically increase with the dose
and then plateau after reaching the level of saturation. Let (k; 0; 1; ) = k denote
the ecacy probability for dose level k. We model ecacy using a logistic model with
plateau parameter  , as follows:
logit(k) = 0 + 1(vk1(k < ) + v1(k  )); (3)
where 0 and 1 > 0 are unknown parameters. The plateau parameter  is an integer
between 1 and K that indicates at which dose level the dose-ecacy curve reaches the
plateau. When the dose level is lower than  , ecacy monotonically increases with
the dose, and when the dose level is equal to or higher than  , ecacy plateaus with
a constant dose eect 1v . In model (3), the \eective" dose vk is determined in a
similar way as before. That is, we rst elicit prior estimates of parameters ~k, ~0, ~1
and ~ from physicians, and then obtain the value of vk by back-solving the dose-ecacy
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model as follows, vk =
n
log

~k
1 ~k

  ~0
o
=~1. In order to make vk identiable, we
require ~1 < : : : < ~K (note that this does not mean that the true value of k is
monotonic). 1(C) denote the indicator function, which takes a value of 1 if C is true
and 0 if C is false.
Let zi denote the binary ecacy outcome (1 = ecacy, and 0 = no ecacy) for
patients i treated at the dose level xi 2 f1; : : : ; Kg, where i = 1; : : : ; N . After the
rst I patients are enrolled into the trial, the likelihood of the ecacy data De =
f(x1; z1); : : : ; (xI ; zI)g is:
L(De j0; 1; ) =
IY
i=1
zixi(1  xi)1 zi :
Letting f(0; 1; ) denote the prior distribution of 0, 1, and  , the posterior is then
given by:
f(0; 1;  jDe) / L(De j0; 1; )f(0; 1; ): (4)
We assume prior distributions are independent and took a vague normal prior N(0; 100)
for the intercept 0 and an exponential distributions with a rate parameter of 1 for 1,
i.e. 1  Exp(1). For the plateau parameter,  , we assign a discrete prior distribution
P( = k) = pk, k = 1; : : : ; K, with
KX
k=1
pk = 1 and 8k; pk  0. When there is prior
information on the location of  , e.g., we know the saturation dosage of the MTA from
pharmacokinetic and pharmacodynamic studies, we can choose a set of pk's to reect the
likelihood of each dose level being the plateau point. When no information is available
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on the plateau location, the uniform prior is recommended with p1 = : : : = pK = 1=K.
After specifying the prior distributions, the posterior distribution is sampled using the
Gibbs sampler.
2.3 Accommodating for delayed ecacy outcome
Unlike toxicity, ecacy often takes a longer follow-up time to assess in practice. Such
a \delayed" outcome causes a logistic issue for implementing adaptive designs: when
a new patient is enrolled and ready for dose assignment, the patients who have been
treated in the trial have not nished their ecacy assessment yet and thus their ecacy
outcomes are not available to apply the adaptive rule to assign a dose for the newly
accrued patient. Designs in the literature that do not enable to account for time-
to-event outcome are forced to \wait" during the ecacy evaluation window. Note
that we cannot ignore the data information from these partially assessed (or followed)
patients, otherwise the resulting estimates are biased [17]. Recently, Liu et al [10]
and Jin et al [12] proposed a systematical approach to handle delayed outcomes for
early phase clinical trials based on Bayesian data augmentation, which enjoys attractive
theoretical and practical properties. For simplicity, we here take the approach of Cheung
and Chappell [18] by weighting the observed data likelihood with the follow-up time.
Specically, let T be a xed time window for evaluating ecacy, and ti denote the
time-to-ecacy of the ith patient. Let Ci;I denote the follow-up time for patient i
prior to the entry of the (I + 1)-th patient (ranging between 0 and T ; i.e. Ci;I =
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min(time arrival of patient(I +1)  time arrival of patienti; T )), and zi;I = 1(ti < Ci;I)
denote the response indicator of patient i prior to the entry of the (I + 1)-th patient.
Before the dose assignment of the (I + 1)-th patient (corresponding to a new cohort),
the weighted likelihood of the ecacy data De = f(x1; z1;I ; w1;I); : : : ; (xI ; zI;I ; wI;I)g
obtained from the rst I patients is given by
L(De j0; 1; ) =
IY
i=1
(wi;Ixi)
zi;I (1  wi;Ixi)1 zi;I ;
where wi;I takes the form of \adaptive" weights proposed by Cheung and Thall[19],
given by
wi;I =
8>><>>:
1 if ti  Ci;I
# fj : tj  Ci;I and Cj;I = Tg+ Ci;I=T
# fj : tj  T and Cj;I = Tg+ 1 if ti > Ci;I :
where # fj : tj  T and Cj;I = Tg is the number of patients who experienced toxicity
(i.e., tj  T ) and completed the followup (i.e., Cj;I = T ) before the entry of the
(I + 1)-th patient; and Ci;I=T is the proportion of the time that patient i was followed
compared to the full follow-up time T before the entry of the (I +1)-th patient. Under
this weight function, the data (i.e. zi;I) from patients whose ecacy outcomes have
been observed receive a full weight of wi;I = 1 (i.e., the rst line of the weights). For
patients whose ecacy outcome has not been observed by the entry of the (I + 1)-th
patient, their weight is the ratio between the number of patients that have experienced
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ecacy at some point before the follow up of patient i plus the fraction of time of
the window T that these patients have been followed up and the total the number of
patients that have experienced ecacy within the window T + 1 (i.e., the second line of
the weights). If many patients experience ecacy early on in the window T (before the
point up to which patient i has been followed up), then the weight of a patient i whose
ecacy outcome has not been observed will be higher than if many patients at this
dose experience ecacy later on. If, however, ecacy occurs later on in the window T
then higher weight is only given the longer a patient has been observed. In general, wi;I
monotonically increases with the follow-up time Ci;I from 0 to 1. That is, the longer
we follow a patient, the more condence we have about that patient's current ecacy
outcome.
2.4 Plateau estimation
Using the Gibbs sampler, we have estimated the posterior probability, k, of the k
th
dose being the plateau point, i.e. P( = kjdata), given by
k =
pk
ZZ
L(0; 1jk;De)f(0; 1)d1d0
KX
=1
p
ZZ
L(0; 1j;De)f(0; 1)d1d0
:
The estimation of the plateau is dicult because it poses an ethical dilemma in
the sense that there is a conict between estimating correctly the optimal dose (which
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requires allocating patients to most or all doses) and allocating more patients to the
currently estimated best dose level (which is, in a sense, being greedy). If the dose
allocation is greedy too early, then it is more likely that the recommended dose level at
the end of the trial will be incorrect. This is because the greedy algorithms that choose
each successive action by myopically optimizing a decision criterion can get stuck at
a suboptimal action [20, 21, 22]. In this paper, being myopic would be to select the
plateau location at the dose level corresponding to the highest posterior probability (as
in [13]). The algorithm, by repeatedly selecting the sub-optimal action, fails to obtain
enough data to identify the true optimal dose at the end of the trial. On the other hand,
if the dose allocation is greedy too late, then many patients will be exposed to wrong
dose levels. This problem is sometimes known as the \exploitation versus exploration"
dilemma, which has been recognized in dose-nding clinical trials [23, 24, 25] and other
contexts, e.g., phase II-III trials [26, 27, 28].
To address the above issue, we proposed two new dose-assignment rules as follows,
 MTA-RA - Adaptive randomization: Randomize the plateau to a dose lo-
cation based on k's. Specically, let R denote the set of doses whose posterior
probabilities of being the plateau point was close to the largest one with a dier-
ence less than a positive threshold s1, i.e.
R =

j :
 max1kK(k)  j
  s1; 1  j  K :
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In other words, R contains a set of doses that are most likely to be the plateau
point. We sample the plateau estimate to dose k 2 R with a re-normalized
probability k
,X
j2R
j . The value of the threshold s1 should be calibrated by
simulation studies. In practice, this can be done as follows: rst dene a set of
representative dose-toxicity scenarios that may be encountered in the trial, and
then conduct simulation under dierent values of s1 to evaluate the performance
of the design. This is a trial-and-error process and may involve repeatedly tuning
the values of s1 based on the simulation results. The goal is to nd the values of s1
that yield good overall performance across dierent scenarios (e.g., the percentage
of correct selection, the number of patients exposed to over-toxic doses or under-
toxic doses). Such a calibration based approach has been widely used in clinical
trial designs [29, 30, 31, 32, 33]. One version of the threshold we found that
generally works well in our simulation study is s1 = 0:20
 
1  I
N

. By letting
s1 depend on the current sample size I, the threshold is more liberal at the
beginning of the trial when we have high uncertainty on model estimates, and
the threshold becomes more stringent toward the end of the trial when we have
more data to estimate the model. The posterior ecacy probabilities, k, are
then estimated as the mean of the ecacy probabilities calculated using only the
MCMC samples including the estimated plateau parameter. Whatever the chosen
threshold, at the end of the trial the plateau location is determined at the dose
with the highest posterior probability so that there is no more randomization for
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dose recommendation.
 MTA-PM - Posterior ecacy probabilities: Assign plateau to the highest
dose where we see a big drop on the estimates of ecacy probabilities. More
precisely, x the plateau location at each possible dose level and estimate posterior
ecacy probabilities. Then perform Bayesian model averaging on the estimated
posterior ecacy probabilities
k = (dk; 0; 1; ) =
KX
=1
(dk; 0; 1j)~ ()
The plateau is determined at dose
k = max
n
j; 1  j  K; ^j   ^j 1  s2
o
;
where cuto s2 can be interpreted as the minimal ecacy dierence of practi-
cal importance. The value of s2, which is a constant, should be calibrated by
simulation to ensure good design operating characteristics.
Ecacy probabilities, k, are then re-evaluated so that ecacy at doses higher than
the plateau are set equal to the ecacy posterior probability estimated at the plateau
point.
We also tried other model selection criteria for plateau determination such as the
DIC (Deviance Information Criterion) or the PPL (Posterior Predictive Loss) which
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we chose not to present in this paper as results were not satisfying. Notice, the two
approaches presented enable determination of the plateau location at each step. They
are expressed in terms of plateau parameter randomization. Equivalently we could have
estimated posterior probabilities and expressed them in terms of patients randomization
at a dose. We choose this way of presenting the method as the description is more
readable and intuitive.
2.5 Dose-nding algorithm
At the beginning of the trial, the posterior estimates of toxicity and ecacy probabilities
typically are not reliable due to the limited amount of data [34, 35, 36, 37, 33]. To gather
enough information for estimating model parameters, we implement the following start-
up phase. Taking a cohort size of 3, we treat the rst cohort of patients at the lowest
dose level 1, and if no toxicity is observed, we escalate to dose level 2 for treating the
second cohort. We continue this dose escalation until we encounter the rst toxicity.
Once a toxicity is observed or the highest dose level is reached, the start-up phase ends
and we switch to the model-based dose-nding phase, where patients are treated in
cohort size of c. If c = 1, patients are treated one by one.
Let  and  denote the pre-specied toxicity upper bound and ecacy lower bound,
respectively. Let nk;I denote the number of patients treated at dose level k. We shall
consider that dose level k is admissible if it satises the safety requirement
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P ( k > ) < LT (5)
and also the ecacy requirement
P (k > )  LE1(nk;I > max(c; 3)); (6)
where LT and LE are the respective probability thresholds for toxicity and ecacy.
Note that the ecacy requirement (6) at one dose takes eect only when more than
one cohort (or 3 patients) is treated at that dose, as controlled by the indicator function
1(nk;I > max(c; 3)). This is to ensure that we have some data to reliably evaluate the
ecacy criterion, given that the ecacy model is relatively complicated.
Let k denote the current dose level and h denote the highest dose level that has
been used previously to treat patients, prior to the entry of the new cohort of patients.
We use B = fk0; 1  k0  max(min(k + 1; K); h)g to denote the set of doses that are
not one level higher than the current dose k or more than h, and A to denote the set
of admissible doses in B. To assign a dose to the incoming cohort, we t the proposed
model using the data collected from the rst I patients enrolled into the trial. The next
incoming (I + 1)-th patient (or the new cohort) is assigned to the dose level with the
highest ecacy in A:
dnext = min

argmax
j2A

^j

If several dose levels are possible, it means that the ecacy plateau is reached and
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among them the dose with the lowest toxicity is selected. Note that although our dose
assignment rule seems greedy (i.e., always assign the incoming patient to the dose level
with the highest estimate of ecacy), it actually is not. This is because, as described
previously, our estimate of the plateau (i.e., the optimal dose with the highest ecacy)
is randomized among several promising doses. As a result, under our dose assignment
rule, the new patient has chances to be assigned to the doses whose estimate of ecacy
are not, but close to, the highest, thereby overcoming the drawback of the conventional
greedy algorithm that tends to get stuck in some local suboptimal doses.
We continue the above dose assignment processes until the maximum sample size
is reached. At the end of the trial, we select the optimal dose as the lowest dose level
that is admissible and has the highest estimate of ecacy among all doses tested during
the trial. At any time during the model-based dose-nding phase, if all doses are not
admissible, we terminate the trial to protect patients from overly toxic or futile doses.
To summarize, after a start-up phase, the two proposed rules estimate the dose
of the plateau location and then assign the next cohort to the admissible dose with
the highest estimated ecacy and among them with the lowest toxicity according to
plateau location.
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3 Numerical Studies
3.1 Simulation
We simulated 2000 independent phase I/II trials to evaluate the operating character-
istics of the proposed design. We assumed 6 dose levels and considered 10 scenarios
(Table 1) with dierent locations of the true optimal dose. These scenarios cover a
wide range of dose-toxicity and dose-ecacy relationships we may encounter in prac-
tice. The pre-specied toxicity upper bound and ecacy lower bound was xed at
 = 0:35 and  = 0:20, respectively. The maximum sample size was N = 60 and the
cohort size was c = 3 patients. The trial started at the lowest dose d1. We took the
initial guesses of toxicity and ecacy probabilities as (0.02, 0.06, 0.12, 0.20, 0.30, 0.40)
and (0.12, 0.20, 0.30, 0.40, 0.50, 0.59), respectively, to obtain the \eective" doses uk
and vk used in the toxicity and ecacy models. First, we have considered toxicity and
ecacy independently, ignoring possible correlation.
We set the toxicity threshold as LT = 0:90 and the ecacy threshold as LE = 0:40.
We assumed that the patient accrual followed a Poisson process with the rate of 0.28
patients per week, i.e. approximately one patient every 3.5 weeks. We assumed that
toxicity was quickly ascertainable, as the majority of phase I trial designs, such that
when the next new patient arrives, the toxicity outcome has been observed for all
patients who have enrolled into the trial. We supposed that the evaluation of ecacy
required 7 weeks, i.e. T = 7 weeks. Under each scenario, we assumed that at each dose,
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the time to ecacy followed an exponential distribution Exp(). The parameter  was
chosen such that at the end of the follow-up, the ecacy rate of each dose matched
those displayed in Table 1, i.e.,  =   log(1  k)=T . As a result, the value of  had to
vary across doses.
For convenience, we refer to the proposed design with the rst plateau determi-
nation procedure based on randomization as the MTA-RA, and the proposed design
with the second plateau determination procedure based on posterior mean of ecacy
probabilities as the MTA-PM.
3.2 Compared designs
We compared the proposed design with the methods proposed by Hunsberger et al [4]
(denoted as HRDK) and the method proposed by Thall and Cook [38] (denoted as
TC). As HRDK and TC designs assume that the ecacy endpoint is binary, quickly
ascertainable, when implementing these two designs, we waited for the ecacy response
of treated patients to be completely observed before enrolling a new cohort of patients.
As a result, the comparison inherently favors the HRDK and TC designs because these
designs are based on full information (i.e., all patients' outcomes are fully observed),
while our approach is based on partial information. For the same reason, our method
leads to substantially shorter trial durations because it does not require waiting for the
ecacy outcome and treats patients in real time.
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HRDK
HRDK is placed in the same context of ecacy plateau than our method. However,
HRDK design considers ecacy as the only endpoint for dose nding and assumes that
the ecacy is binary and immediately ascertainable. Toxicity is assumed acceptable
and not taken into account. Therefore, for the simulation study, the results comparison
can only be made when toxicity is acceptable at all dose levels or when the plateau is
reached before the toxicity upper bound. For HRDK, we took the cohort size as 10 such
that the total sample size matches that of the proposed design (i.e., N = 60) when all
six dose levels are explored. We implemented this approach in R using \lm" function.
TC
TC is a more complex phase I/II Bayesian dose-nding design based on trade-os
between the probabilities of ecacy and toxicity. It enables to select the optimal dose
in terms of both toxicity and ecacy. For TC, as for the proposed method, the same
maximum sample size for 60 patients and cohort size of 3 patients were used. The
toxicity and ecacy upper and lower limits were specied as T = 0:35 and E = 0:20,
and pT and pE are xed probability cutos both chosen equal to 0:10 as chosen in
the original paper [38]. Simulations were performed using the free \ETox" software
available on the MD Anderson Biostatistics software website
(https://biostatistics.mdanderson.org/SoftwareDownload). As no data are avail-
able from real clinical trials, we let the default parameters in the software for other
settings.
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3.3 Scenarios
In practice, when a dose-nding design missed the optimal dose, but selected a safe
dose that has the same ecacy as the optimal dose (although it may have higher dose
level than the optimal dose), it is still of interest to physicians. We refer to the set of
admissible doses that have the same ecacy as the optimal dose as \correct" doses.
For example, in scenario 1, dose level 6 is a \correct" dose, because it has the same
ecacy probability of 0.8 as the optimal dose (i.e., dose level 5).
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Table 1: Selection percentage and number of patients (shown in parentheses) allo-
cated to each dose under the HRDK design, TC design, and the proposed MTA-RA
and MTA-PM designs. In bold are given the optimal doses, and correct doses are
underlined.
Dose levels Early
Design 1 2 3 4 5 6 stop
Scenario 1
( k; k) (0.005,0.01) (0.01,0.10) (0.02,0.30) (0.05,0.50) (0.10,0.80) (0.15,0.80)
HRDK 0.1 (10.0) 0.6 (10.0) 1.3 (10.0) 1.3 (9.9) 38.2 (9.8) 58.4 (9.8) 0.0
TC 0.0 (3.2) 0.0 (3.0) 0.0 (3.2) 4.5 (6.9) 45.0 (23.5) 50.5 (20.2) 0.0
MTA-RA 0.0 (3.3) 0.1 (3.7) 0.6 (5.0) 4.6 (8.5) 58.5 (21.4) 35.7 (17.8) 0.7
MTA-PM 0.2 (3.9) 0.1 (3.7) 7.3 (6.9) 12.3 (9.3) 68.7 (29.8) 10.1 (6.0) 1.4
Scenario 2
( k; k) (0.01,0.40) (0.05,0.40) (0.10,0.40) (0.25,0.40) (0.50,0.40) (0.70,0.40)
HRDK 25.3 (10.0) 26.4 (10.0) 23.3 (10.0) 12.8 (5.8) 7.7 (3.5) 4.5 (1.5) 0.0
TC 79.5 (48.3) 1.5 (1.3) 11.5 (4.8) 7.5 (4.9) 0.0 (0.5) 0.0 (0.1) 0.0
MTA-RA 63.5 (17.0) 19.3 (13.0) 8.3 (10.9) 5.4 (11.7) 2.7 (6.4) 0.4 (0.8) 0.5
MTA-PM 70.2 (34.4) 18.6 (13.3) 8.8 (8.0) 1.4 (3.0) 0.2 (1.0) 0.0 (0.1) 0.9
Scenario 3
( k; k) (0.01,0.25) (0.02,0.45) (0.05,0.65) (0.10,0.65) (0.20,0.65) (0.30,0.65)
HRDK 0.7 (10.0) 5.6 (10.0) 28.9 (10.0) 26.4 (9.8) 21.5 (8.4) 16.8 (4.7) 0.0
TC 37.0 (27.3) 1.0 (2.1) 4.5 (4.2) 38.5 (17.6) 18.5 (7.3) 1.5 (1.4) 0.0
MTA-RA 2.0 (6.8) 14.5 (10.1) 48.3 (14.6) 20.1 (12.8) 8.7 (10.7) 6.5 (5.1) 0.0
MTA-PM 8.9 (8.3) 23.5 (14.2) 49.8 (23.8) 15.6 (9.8) 1.8 (2.8) 0.0 (0.9) 0.5
Scenario 4
( k; k) (0.01,0.05) (0.02,0.25) (0.05,0.45) (0.10,0.70) (0.25,0.70) (0.50,0.70)
HRDK 0.1 (10.0) 0.9 (10.0) 3.0 (10.0) 27.0 (9.9) 31.6 (9.8) 37.3 (8.9) 0.0
TC 0.0 (4.5) 0.0 (3.2) 1.5 (4.5) 62.0 (30.0) 35.5 (16.2) 1.0 (1.5) 0.0
MTA-RA 0.0 (4.0) 1.0 (5.7) 8.5 (10.0) 53.9 (17.4) 27.5 (15.7) 8.9 (7.1) 0.4
MTA-PM 0.3 (4.3) 3.5 (5.6) 22.6 (13.4) 47.0 (22.0) 24.8 (12.9) 0.2 (1.0) 1.7
Scenario 5
( k; k) (0.01,0.10) (0.05,0.35) (0.15,0.60) (0.20,0.60) (0.45,0.60) (0.60,0.60)
HRDK 0.0 (10.0) 2.6 (10.0) 27.5 (10.0) 26.6 (10.0) 25.1 (9.1) 18.0 (5.3) 0.0
TC 2.0 (7.6) 4.0 (5.3) 30.5 (15.9) 61.5 (27.6) 3.0 (3.3) 0.0 (0.3) 0.0
MTA-RA 0.1 (5.5) 8.7 (9.1) 55.4 (17.4) 26.4 (15.7) 8.4 (10.2) 1.0 (2.0) 0.2
MTA-PM 1.5 (5.8) 12.8 (10.1) 53.4 (25.6) 27.5 (14.7) 2.0 (2.7) 0.0 (0.1) 2.9
Scenario 6
( k; k) (0.01,0.05) (0.05,0.10) (0.10,0.20) (0.20,0.35) (0.30,0.55) (0.50,0.55)
HRDK 3.9 (10.0) 5.4 (10.0) 6.4 (10.0) 5.2 (8.9) 33.8 (8.5) 45.2 (8.3) 0.0
TC 0.0 (4.8) 0.5 (3.7) 11.5 (8.3) 37.0 (18.8) 41.5 (17.6) 5.5 (5.2) 4.0
MTA-RA 0.0 (4.7) 1.0 (5.8) 4.7 (8.6) 18.5 (13.0) 55.2 (17.8) 12.7 (7.2) 8.0
MTA-PM 3.2 (8.7) 0.6 (5.7) 8.6 (9.3) 19.9 (11.9) 39.5 (15.5) 2.6 (2.6) 25.7
Scenario 7
( k; k) (0.02,0.30) (0.07,0.50) (0.13,0.70) (0.17,0.73) (0.25,0.76) (0.30,0.77)
HRDK 1.0 (10.0) 4.5 (10.0) 20.1 (10.0) 22.6 (9.8) 24.6 (8.8) 27.2 (6.1) 0.0
TC 57.5 (37.2) 2.0 (2.4) 12.0 (7.0) 23.5 (10.9) 4.0 (2.0) 1.0 (0.5) 0.0
MTA-RA 1.4 (6.1) 8.6 (9.0) 38.7 (15.1) 22.9 (13.8) 16.6 (11.1) 11.8 (4.9) 0.0
MTA-PM 10.1 (8.8) 22.9 (15.1) 48.9 (24.6) 16.2 (9.3) 1.5 (1.7) 0.0 (0.4) 0.5
Scenario 8
( k; k) (0.03,0.30) (0.06,0.50) (0.10,0.52) (0.20,0.54) (0.40,0.55) (0.50,0.55)
HRDK 4.2 (10.0) 23.5 (10.0) 24.3 (10.0) 21.8 (8.9) 14.7 (5.8) 11.5 (3.5) 0.0
TC 55.5 (35.7) 2.5 (2.6) 14.0 (7.2) 25.5 (12.4) 2.0 (1.8) 0.0 (0.4) 0.0
MTA-RA 13.5 (10.4) 43.7 (15.0) 20.0 (12.8) 12.5 (12.0) 8.3 (8.1) 2.0 (1.8) 0.1
MTA-PM 25.5 (16.0) 43.9 (22.4) 24.6 (15.1) 5.1 (4.8) 0.4 (1.3) 0.0 (0.2) 0.6
Scenario 9
( k; k) (0.05,0.01) (0.10,0.02) (0.25,0.05) (0.55,0.35) (0.70,0.55) (0.90,0.70)
HRDK 4.4 (10.0) 1.1 (10.0) 2.6 (10.0) 2.3 (9.2) 15.8 (9.1) 73.6 (9.0) 0.0
TC 0.0 (3.4) 0.0 (3.2) 8.5 (9.5) 9.5 (11.5) 0.5 (1.6) 0.0 (0.3) 81.5
MTA-RA 0.0 (5.8) 0.0 (5.9) 3.0 (7.5) 5.5 (10.9) 0.0 (2.3) 0.0 (0.3) 91.6
MTA-PM 0.1 (6.1) 0.0 (6.0) 2.7 (6.9) 6.6 (10.2) 0.2 (3.2) 0.0 (0.3) 90.4
Scenario 10
( k; k) (0.50,0.40) (0.60,0.55) (0.69,0.65) (0.76,0.65) (0.82,0.65) (0.89,0.65)
HRDK 4.6 (10.0) 14.4 (10.0) 28.7 (10.0) 23.8 (9.1) 16.7 (6.6) 11.8 (3.6) 0.0
TC 10.5 (18.7) 2.0 (0.8) 0.0 (0.3) 0.0 (0.1) 0.0 (0.0) 0.0 (0.0) 87.5
MTA-RA 10.9 (16.1) 0.2 (4.0) 0.0 (1.0) 0.0 (0.2) 0.0 (0.0) 0.0 (0.0) 89.0
MTA-PM 10.9 (16.3) 0.1 (4.7) 0.0 (0.7) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 89.0
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3.4 Results
As shown in Table 1 and Table 2, the proposed MTA-RA and MTA-PM designs gen-
erally outperformed HRDK design. TC performed better than MTA approaches in
scenarios 2 and 4, while MTA-RA performed as well as or better in terms of both the
selection of the optimal and correct dose levels and the number of patients allocated to
the optimal doses in scenarios 1, 3, 6, 7 and 8. In scenario 1, all doses were safe with
toxicity probabilities lower than the upper limit, and thus the dose selection was largely
guided by ecacy. The percentage of correct selection of the optimal dose (PCS-OD)
was 38.2%, 45.0% , 58.5% and 68.7% under HRDK, TC, MTA-RA and MTA-PM, re-
spectively. The MTA-PM design performed best with the highest PCS-OD. In scenarios
2 the plateau was reached at the lowest dose level, in this case TC performs better. We
can observe for this scenario that the PCS-OD of TC and the proposed designs more
than doubled that of the HRDK design. In scenario 3, the third dose is the optimal dose.
The PCS-OD of the proposed designs were about 50%, while that of the HRDK design
was 28.9% and that of the TC design fall down to 4.5%. The TC design tended to select
a higher dose (i.e., the fourth dose) as the optimal dose. Similar results were observed
in scenarios 4 to 6. In scenarios 7 and 8, where the ecacy does not exactly plateau
but increases by small amount until a dierence of 10% from the ecacy plateau, the
proposed designs were still able to select the target dose with the highest percentage
and substantially outperformed the HRDK and TC designs. In scenarios 9 and 10,
none of the doses were admissible and the trial should be terminated. Specically, in
25
Table 2: Selection percentages of the optimal dose and correct doses.
Scenarios
Design 1 2 3 4 5 6 7 8
Optimal dose selection percentage
HRDK 38.2 25.3 28.9 27.0 27.5 33.8 20.1 23.5
TC 45.0 79.5 4.5 62.0 30.5 41.5 12.0 2.5
MTA-RA 58.5 63.5 48.3 53.9 55.4 55.2 38.7 43.7
MTA-PM 68.7 70.2 49.8 47.0 53.4 39.5 48.9 43.9
Correct dose selection percentage
HRDK 96.6 87.8 93.6 58.6 54.1 33.8 94.5 69.6
TC 95.5 100.0 63.0 97.5 92.0 41.5 40.5 42.0
MTA-RA 94.2 96.5 83.6 81.4 81.8 55.2 90.0 76.2
MTA-PM 78.8 99.0 67.2 71.8 80.9 39.5 66.6 73.6
scenario 9, the rst three doses was safe but their ecacy was unacceptably low, and
the remaining doses were overly toxic; in scenario 10, all doses were overly toxic. In
these two scenarios, the two proposed designs early terminated the trial more than 90%
of the time, as well as TC in 81.5%. The HRDK design did not consider toxicity, thus
failed to stop the trial in both scenarios.
Table 2 summarizes the selection percentage of the optimal dose and correct doses
under 8 scenarios. We can see that the selection percentage of the \correct" doses under
the proposed designs were mostly over 70%. Between the two proposed design, MTA-
RA appeared to have slightly better and more robust performance than the MTA-PM,
thus we recommend it for general use in practice.
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3.5 Sensitivity analysis
3.5.1 Non-monotonic dose-ecacy relationships
Our designs assume that the dose-ecacy curve increases initially and then plateaus.
We conducted a sensitivity analysis to evaluate the performance of the proposed design
when the dose-ecacy curve was umbrella shaped (i.e., ecacy rst increases and then
decreases, see scenarios 1 and 2 in Table 3), monotonically increasing (scenario 3 in
Table 3), or monotonically decreasing (scenario 4 in Table 3). The sample size was 36
patients with a cohort size of 3, and we took  = 0:35 and  = 0:20. The simulation
results (see Table 3) show that the proposed design performed well under these dier-
ent shapes of dose-ecacy curves. The selection percentages of the target dose were
comparable to these reported in Table 1, suggesting that the proposed designs were not
sensitive to the violation of the increasing-then-plateau assumption.
3.5.2 Prior distributions
We also evaluate the robustness of the proposed designs in terms of prior distribution.
We changed the prior distributions of slope parameters 1 (for toxicity) and 1 (for
ecacy) from Exp(1) to gamma distribution Gamma(0:5; 0:5). Results are provided in
Table 4. We observe that both proposed methods are generally robust to the choice of
prior distributions. The results are similar to these reported in Table 1.
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Table 3: Sensitivity analysis of the proposed MTA-RA and MTA-PM designs. In bold
are given the optimal doses.
Dose levels
Design 1 2 3 4 None
Scenario 1
(0.01, 0.10) (0.05, 0.35) (0.15, 0.60) (0.25, 0.30)
HRDK 0.1 (9.0) 7.6 (9.0) 81.5 (9.0) 10.8 (8.9) 0.0
TC 2.0 (4.8) 6.0 (5.0) 46.0 (12.6) 45.0 (13.4) 1.0
MTA-RA 1.2 (4.8) 19.6 (8.6) 73.9 (17.1) 3.5 (5.3) 2.0
MTA-PM 13.0 (9.6) 26.5 (10.1) 49.1 (12.9) 0.8 (2.6) 10.7
Scenario 2
(0.10, 0.50) (0.20, 0.70) (0.30, 0.60) (0.50, 0.40)
HRDK 7.4 (9.0) 54.6 (9.0) 34.6 (9.0) 3.3 (5.2) 0.0
TC 67.0 (25.0) 25.0 (7.5) 7.0 (2.7) 0.0 (0.6) 1.0
MTA-RA 30.4 (11.6) 59.6 (14.9) 9.4 (7.3) 0.5 (2.1) 0.2
MTA-PM 38.2 (15.2) 58.4 (17.9) 3.2 (2.4) 0.0 (0.4) 0.3
Scenario 3
(0.05, 0.02) (0.10, 0.28) (0.16, 0.50) (0.22, 0.80)
HRDK 0.0 (9.0) 0.7 (9.0) 5.1 (9.0) 94.2 (8.9) 0.0
TC 0.0 (3.2) 2.0 (4.4) 19.0 (9.0) 78.0 (19.0) 1.0
MTA-RA 0.0 (3.8) 4.4 (5.6) 10.7 (8.0) 82.7 (18.2) 2.3
MTA-PM 1.8 (5.9) 13.4 (7.7) 27.8 (11.1) 49.1 (10.4) 8.0
Scenario 4
(0.05,0.80) (0.10,0.50) (0.16,0.28) (0.22,0.02)
HRDK 86.5 (9.0) 12.5 (9.0) 1.0 (9.0) 0.0 (0.0) 0.0
TC 99.0 (35.0) 1.0 (0.7) 0.0 (0.2) 0.0 (0.1) 0.0
MTA-RA 99.4 (26.3) 0.5 (5.2) 0.0 (3.1) 0.0 (1.4) 0.1
MTA-PM 98.5 (29.5) 1.5 (3.3) 0.0 (2.0) 0.0 (1.2) 0.1
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Table 4: Sensitivity analysis with dierent prior distributions.
Dierent prior distributions: 1, 1   (0:5; 0:5)
sc1 sc2 sc3 sc4 sc5 sc6 sc7 sc8
Optimal dose selection percentage
MTA-RA 61.1 61.9 45.7 56.0 54.8 50.2 38.2 43.5
MTA-PM 68.5 85.0 45.9 49.3 50.5 40.5 39.7 34.3
Correct dose selection percentage
MTA-RA 90.9 96.4 80.8 81.4 78.6 50.2 86.4 74.9
MTA-PM 78.4 99.2 62.8 71.8 76.6 40.5 56.2 57.3
4 Conclusion
We have developed a phase I/II Bayesian dose-nding design for a molecularly targeted
agent alone or in combination with a xed dose of a cytotoxic agent. Our design takes
into account that the ecacy curve may plateau as the dose level increases and focuses
on selecting the optimal dose, i.e. the dose with the lowest toxicity among those with
highest ecacy.
We have proposed two dierent allocation methods. One based on adaptive ran-
domization with posterior probabilities for the plateau parameter, and the other one
based on the dierence between the posterior mean of ecacy probabilities according
to the plateau parameter. On the contrary to our previous work [13] that used a greedy
algorithm for dose estimation-selection based on highest posterior probability, our pro-
posed approaches have found to be robust, and enable to avoid getting stuck in local
maxima when considering many doses. Both allocations give good and similar perfor-
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mance in terms of PCS-OD, but MTA-RA seems more robust across scenarios (always
above 50%). Moreover, it also gives a higher percentage of selection of a correct dose
level (Table 2), that is dose levels with the highest ecacy but not necessarily lowest
toxicity under toxicity restrictions. Our approach outperforms the HRDK design [4],
and performs as well as or better than TC [38] in terms of both the selection of the
optimal and correct dose levels and the number of patients allocated to the optimal
doses in most scenarios (1, 3, 6, 7 and 8, while TC performed better in scenarios 2 and
4). It must be noted that TC contains many settings that need to be calibrated to
which the design are very sensitive. In the absence of clinical trials data, we used the
default values of the provided software.
Furthermore, we have also considered the possibility to apply our design to non-
monotone relationships. In these cases, our design also gives good performance in
general, but MTA-RA performed better in the common case where no plateau is ob-
served across all dose levels. For all these reasons, when a statistician is involved in a
clinical trial where a plateau ecacy or a unimodal relationship is expected, we recom-
mend to use the MTA-RA design. We developed an R-package dfmta which is available
on CRAN.
We have assumed that toxicity is binary and quickly ascertainable while ecacy
may be delayed or late-onset. In some cases, toxicity may also require a long period
of time to be evaluated. We can accommodate such delayed toxicity using a similar
weighting approach. Jin et al [12] considered a more principled missing data approach to
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handle both delayed toxicity and ecacy, which can also be adopted here. We also plan
to develop a new methodology to deal with more complex trials. We are developing a
method for ordinal toxicity and ecacy outcomes using a multinomial logistic regression
model, and selecting the dose based on a utility function. To avoid the exploitation
versus exploration dilemma, dynamic and non-myopic rules could be explored [26, 39,
28], which enable to appropriately balance the dilemma between learning about doses'
ecacy and allocating more patients to the best dose level. We are pursuing this work
with new collaborations; some authors of this paper are exploring the possibility to
apply Bandit algorithms [40, 41] to standard CRM and then to extend it to unimodal
relationship.
Supplementary material
Results of sensitivity analysis on prior distributions can be found in supplementary
material.
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